Physician profile
Nanda N Kumar
NPI 1861595001
$11,037.65
in general payments reported to CMS, 2019-2025
55 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,907 · 2020: $1,103 · 2021: $1,605 · 2022: $1,748 · 2023: $3,674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,252 · Travel and Lodging: $1,422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,251.99 |
| Travel and Lodging | $1,422.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,696.95 | 2021-2023 | Infinity, Proclaim |
| Ucb, INC. | $616.02 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $582.34 | 2019-2023 | |
| Amgen INC. | $551.91 | 2019-2022 | |
| Biogen, INC. | $522.66 | 2019-2023 | Vumerity, Plegridy, Avonex |
| Emd Serono, INC. | $480.44 | 2019-2023 | Mavenclad |
| Acadia Pharmaceuticals INC | $474.16 | 2019-2023 | Nuplazid |
| Genzyme Corporation | $441.82 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $410.61 | 2019-2023 | Ajovy, Austedo |
| Jazz Pharmaceuticals INC. | $386.36 | 2019-2023 | Xywav |
| Neurocrine Biosciences, INC. | $324.06 | 2019-2022 | |
| Kyowa Kirin, INC. | $317.42 | 2019-2023 | Nourianz |
| Harmony Biosciences LLC | $287.59 | 2020-2023 | Wakix |
| Celgene Corporation | $262.77 | 2021-2023 | Zeposia |
| Amneal Pharmaceuticals LLC | $260.42 | 2019-2023 | Rytary |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nanda Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.